Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Improper Inducements
Phase II Study with Ocrelizumab Shows Significant Reduction in Disease Activity for Multiple Sclerosis Patients
Efficacy and Safety of GTR in Comparison to Copaxone® (GATE)
The Prevention of Post-Partum Relapses with Progestin and Estradiol in Multiple Sclerosis (POPART'MUS) trial: rationale, objectives and state of advancement.
Myelin oligodendrocyte glycoprotein-specific T and B cells cooperate to induce a Devic-like disease in mice.
A Study of Efficacy and Safety of Ocrelizumab in Patients with Relapse-Remitting Multiple Sclerosis
Episode 64 with Dr. Helen Tremlett on pediatric MS and the gut microbiome
Episode 71 with Dr. Brian Weinshenker on innovative clinical trials for NMO
Episode 66 with Dr. Jeremy Hobart on optimizing treatment outcomes
Nominations Open for Dystel Prize for MS Research
Gordon Research Conference: Myelin
MS Research Roundup: April 23, 2014
CellCept (Product Insert)
Drug-based modulation of endogenous stem cells promotes functional remyelination in vivo.
Exclusive breastfeeding and the risk of postpartum relapses in women with multiple sclerosis.
LINGO-1 negatively regulates myelination by oligodendrocytes.
Protective effect of breastfeeding in postpartum relapse rate of mothers with multiple sclerosis.
U.S. FDA grants Breakthrough Therapy Designation for Roche’s investigational medicine ocrelizumab in primary progressive multiple sclerosis
Episode 51 with Dr. Luke Lairson on discovery of small molecules to induce remyelination
Efficacy and safety of BG-12 (dimethyl fumarate) and other disease modifying therapies for the treatment of relapsing-remitting multiple sclerosis: a systematic review and mixed treatment comparison.
MS Research Roundup: February 5, 2014
A network meta-analysis of randomized controlled trials for comparing the effectiveness and safety profile of treatments with marketing authorization for relapsing multiple sclerosis.
Ocrelizumab Bests Interferon in Relapsing-Remitting MS
FDA Warns About CCSVI Treatment
The origin and application of experimental autoimmune encephalomyelitis.

Pages